TD Cowen Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM) had its price target increased by TD Cowen from $154.00 to $193.00 in a report released on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

INSM has been the topic of several other reports. Mizuho increased their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Morgan Stanley increased their price objective on shares of Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. The Goldman Sachs Group boosted their target price on Insmed from $114.00 to $142.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Citigroup upgraded Insmed to a “buy” rating in a report on Tuesday, June 10th. Finally, Jefferies Financial Group raised their price objective on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $149.06.

Insmed Trading Up 2.9%

NASDAQ INSM opened at $157.16 on Thursday. The stock has a market capitalization of $33.22 billion, a P/E ratio of -27.52 and a beta of 1.03. The business has a 50 day simple moving average of $132.46 and a 200 day simple moving average of $99.10. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed has a one year low of $60.40 and a one year high of $158.19.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Research analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the sale, the insider owned 54,902 shares of the company’s stock, valued at approximately $7,899,848.78. The trade was a 30.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 277,332 shares of company stock valued at $33,842,327 in the last three months. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. grew its stake in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the period. ORG Partners LLC lifted its holdings in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the last quarter. Hilltop National Bank bought a new position in Insmed during the second quarter worth about $28,000. FNY Investment Advisers LLC purchased a new position in shares of Insmed in the second quarter worth about $33,000. Finally, NBC Securities Inc. bought a new stake in shares of Insmed in the first quarter valued at approximately $49,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.